Glucagon Peptide Market Trend: What’s Driving Demand in 2024?
Title: Glucagon Peptide Market Trend: What’s Driving Demand in 2024? Abstract: In 2024, the glucagon peptide market is propelled by expanding applications beyond diabetes rescue, including obesity management and congenital hyperinsulinemia. Key drivers include the shift toward stable, long-acting GLP-1/glucagon dual agonists (e.g., semaglutide analogs) over native glucagon, which suffers from short half-life and instability. Leading brands (Novo Nordisk, Eli Lilly) dominate via FDA/EMA-approved formulations, while emerging Chinese manufacturers (e.g., Hybio, Ambio) offer cost-competitive, GMP-certified APIs. Technical advantages of synthetic glucagon (high purity >98%, controlled aggregation) outweigh extraction-derived variants. Logistics demand cold-chain compliance (2–8°C) to maintain bioactivity. Market data projects a 12.5% CAGR through 2030, driven by peptide-based weight loss therapies. Selection criteria prioritize purity certificates (HPLC, MS), stability data, and regulatory dossiers (DMF, COA).